Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
06:20am, Friday, 24'th Apr 2026
BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today a
Analyzing Bio-Rad Laboratories (NYSE:BIO) & Haemonetics (NYSE:HAE)
02:26am, Wednesday, 15'th Apr 2026
Bio-Rad Laboratories (NYSE: BIO - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two business
Haemonetics (NYSE:HAE) vs. Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review
01:13am, Friday, 03'rd Apr 2026
Haemonetics (NYSE: HAE - Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses ba
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
04:05pm, Wednesday, 01'st Apr 2026
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
04:15pm, Monday, 30'th Mar 2026
VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
05:43pm, Friday, 20'th Mar 2026
Invenomic sold 498,317 shares of Haemonetics Corporation in the fourth quarter. The quarter-end position value decreased by $24.29 million due to the sale of all the fund's shares.
Here's Why Haemonetics (HAE) is a Strong Value Stock
10:40am, Wednesday, 18'th Mar 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
10:50am, Monday, 16'th Mar 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
11:20am, Thursday, 12'th Mar 2026
HAE's NexSys PCS adoption and hospital recovery signal growth ahead, but a leveraged balance sheet and stiff competition still cloud the stock's outlook.
Elo Mutual Pension Insurance Co Takes $829,000 Position in Haemonetics Corporation $HAE
03:58am, Saturday, 07'th Mar 2026
Elo Mutual Pension Insurance Co bought a new stake in Haemonetics Corporation (NYSE: HAE) during the third quarter, according to the company in its most recent disclosure with the Securities and Excha
Allspring Special Small Cap Value Fund Q4 2025 Portfolio Review
05:50am, Wednesday, 04'th Mar 2026
The largest contributor was Haemonetics Corp., a medical device company focused on products related to blood collection and management. Another top contributor was Mueller Industries, Inc., an industr
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Here's Why Haemonetics (HAE) is a Strong Value Stock
10:41am, Monday, 02'nd Mar 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Touchstone Small Cap Fund Q4 2025 Portfolio Review
07:20am, Monday, 02'nd Mar 2026
The Touchstone Small Cap Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell 2000® Index, for the quarter ended December 31, 2025. The best performing stocks based on relative
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
04:15pm, Monday, 23'rd Feb 2026
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today an
